Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development ...
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today ...
GlobalData on MSN
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...
Investor's Business Daily on MSN
Alumis stock catapults more than 95% as biotech takes on J&J, Protagonist in psoriasis
Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against ...
Cash, cash equivalents and marketable securities of $678.8 million as of September 30, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / November 6, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback